PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY THERAPY AREA • Segmentation by therapy area • Comparison by therapy area • Oncology – Market size and forecast 2017-2022 • CNS – Market size and forecast 2017-2022 • Ophthalmology – Market size and forecast 2017-2022 • Rare diseases – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by therapy area PART 08: PIPELINE PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Growing research in gene therapy for CVDs and orphan diseases • Growing strategic alliances • Increasing government initiatives PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Biogen • Gilead • Novartis • Orchard Therapeutics • Spark Therapeutics PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market: Global regenerative medicines market Exhibit 02: Global regenerative medicines market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global gene therapy market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global gene therapy market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Global gene therapy market – Market share by therapy area 2017-2022 (%) Exhibit 19: Comparison by therapy area Exhibit 20: Global gene therapy market by oncology – Market size and forecast 2017-2022 ($ mn) Exhibit 21: Global gene therapy oncology market – Year-over-year growth 2018-2022 (%) Exhibit 22: Global gene therapy market by CNS – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global gene therapy market by CNS – Year-over-year growth 2018-2022 (%) Exhibit 24: Global gene therapy market by ophthalmology – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global gene therapy market by ophthalmology – Year-over-year growth 2018-2022 (%) Exhibit 26: Global gene therapy market by rare diseases – Market size and forecast 2017-2022 ($ mn) Exhibit 27: Global gene therapy market by rare diseases – Year-over-year growth 2018-2022 (%) Exhibit 28: Global gene therapy market by others – Market size and forecast 2017-2022 ($ mn) Exhibit 29: Global gene therapy market by others – Year-over-year growth 2018-2022 (%) Exhibit 30: Market opportunity by therapy area Exhibit 31: Global gene therapy market pipeline: Overview Exhibit 32: Gene therapy in pipeline: Overview Exhibit 33: Customer landscape Exhibit 34: Global gene therapy market – Market share by geography 2017-2022 (%) Exhibit 35: Regional comparison Exhibit 36: Gene therapy market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 37: Gene therapy market in Americas – Year-over-year growth 2018-2022 (%) Exhibit 38: Gene therapy market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 39: Gene therapy market in EMEA – Year-over year-growth 2018-2022 (%) Exhibit 40: Gene therapy market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 41: Gene therapy market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: Biogen – Overview Exhibit 50: Biogen – Business segments Exhibit 51: Biogen – Organizational developments Exhibit 52: Biogen – Geographic focus Exhibit 53: Biogen – Key offerings Exhibit 54: Biogen – Key customers Exhibit 55: Gilead – Overview Exhibit 56: Gilead – Business segments Exhibit 57: Gilead – Organizational developments Exhibit 58: Gilead – Geographic focus Exhibit 59: Gilead – Key offerings Exhibit 60: Gilead – Key customers Exhibit 61: Novartis: Overview Exhibit 62: Novartis – Business segments Exhibit 63: Novartis – Organizational developments Exhibit 64: Novartis – Geographic focus Exhibit 65: Novartis – Segment focus Exhibit 66: Novartis – Key offerings Exhibit 67: Novartis – Key customers Exhibit 68: Orchard Therapeutics – Overview Exhibit 69: Orchard Therapeutics – Business segments Exhibit 70: Orchard Therapeutics – Organizational developments Exhibit 71: Orchard Therapeutics – Key offerings Exhibit 72: Orchard Therapeutics – Key customers Exhibit 73: Spark Therapeutics – Overview Exhibit 74: Spark Therapeutics – Business segments Exhibit 75: Spark Therapeutics – Organizational developments Exhibit 76: Spark Therapeutics – Key offerings Exhibit 77: Spark Therapeutics – Key customers

Biogen Gilead Novartis Orchard Therapeutics Spark Therapeutics